Emerson process analytics 2026: Rosemount QX1000 and PACEdge 3.0
A hybrid laser-paramagnetic gas analyzer and a refreshed edge AI platform mark Emerson's two most significant process analytics moves in the first three quarters of fiscal 2026.
Articles by Daniel Marsh
Anton Paar 2026: compact inline refractometers and a beverage analyzer refresh
Anton Paar extended its inline sensor portfolio in 2025-2026 with compact L-Rix refractometers and a fourth-generation Cobrix beverage analyzer family, and added subsidiaries in three new markets.
Evonik Q2 2026: Crosslinkers and Polymers Drive Best Quarter in Four Years
Evonik's Q2 2026 adjusted EBITDA surged 24% to €630 million as crosslinkers, high-performance polymers, and amino acids defied macro headwinds - a signal worth parsing for the process analytics sector.
Shimadzu Q1 FY2027: record revenue and upgraded outlook on Tescan deal
Shimadzu posted a sixth consecutive record quarter with Q1 FY2027 net sales of ¥130.6 billion, then raised its full-year guidance to ¥620 billion as the Tescan electron-microscope acquisition nears consolidation.
Yokogawa process analyzer line 2026: what has changed
Yokogawa's H1 2026 process-analyzer moves were not new hardware. A February deal with CMC Solutions makes Yokogawa the global distributor of PEMS software, extending emissions monitoring beyond hardware CEMS.
ABB process analytics 2026: CCUS bundle, Automation Extended, Rotork bid
ABB's 2026 measurement and analytics posture combines a February CCUS analyzer bundle, an Automation Extended AI wrapper booked in Q1, and a July agreement to acquire Rotork for USD 5.5 billion in cash.
Roche H1 2026: Diagnostics up 3% at CER as China drag persists
Roche's Diagnostics division posted CHF 6.7 billion in H1 2026, up 3% at constant exchange rates and 6% excluding China, where healthcare pricing reform continues to weigh on the segment.
Thermo Fisher Q2 2026: Analytical Instruments margin jumps 420 bps to 23.0%
Thermo Fisher reported Q2 2026 revenue of $11.99 billion, up 10%, with the Analytical Instruments segment growing 7% to $1.85 billion and adjusted operating margin lifting 420 basis points to 23.0%.
Metrohm process analytics 2026: titration and IC updates for continuous processes
Metrohm opened a Houston application facility and helped shape ISO 18127 for combustion ion chromatography; here is what changed in its process analytics portfolio through mid-2026 and what did not.
Air Liquide Q1 2026: EUR 7.0B sales, EUR 5.5B investment backlog
Air Liquide reported Q1 2026 sales of EUR 7,028 million on April 28, up 3.4 percent excluding currency and energy, with a record EUR 5.5 billion investment backlog and DIG Airgas closed in January.
Specialty chemicals digital transformation: what is actually deployed
Across BASF, Lanxess, Solvay, Syensqo, and Wacker, only Solvay and Syensqo published 2025 plant counts and outcomes against named digital platforms. The others restructured, paused, or went quiet.
Linde Q1 2026: $8.78B sales, $7.1B sale-of-gas backlog
Linde reported first-quarter 2026 sales of $8,781 million on May 1, with adjusted operating margin at 30.0% and a $7.1 billion contractual sale-of-gas project backlog.
Lonza confirms 2026 outlook in Q1 trading update, capex program continues
Lonza's May 8 Q1 2026 trading update reaffirmed 11-12% CER sales growth guidance and a CORE EBITDA margin above 32%, with the Vacaville site fully integrated and the Visp and Portsmouth build-outs still on the books.
BASF, Dow, DuPont Q1 2026: split signals from the chemicals supermajors
BASF held sales close to flat, Dow swung to a GAAP Q1 loss on heavier costs, and DuPont raised full-year guidance after a 4 percent sales lift - three Q1 2026 prints that diverge sharply on margin trajectory.
Tornado folded into Bruker brand; Timegate stays independent with new partner
Tornado Spectral Systems' separate brand has been retired into Bruker's process Raman portfolio. Timegate Instruments stays independent in Oulu, with a new Central European distributor signed for analytica 2026.
Analytical instruments capex 2026: which end markets are funding orders
Cross-read of Q1 2026 prints from six analytical-instrument vendors: bioprocessing and semiconductor metrology are funding capex, while academic and core industrial demand stays cautious.
Waters Q1 2026: first combined quarter with BD biosciences and diagnostics
Waters Corporation posted $1.267 billion in Q1 2026 revenue, its first reporting period after closing the BD biosciences and diagnostics acquisition on February 9.
Revvity Q1 2026: revenue beats, China Immunodiagnostics carved out
Revvity reported Q1 2026 revenue of $711 million and signed a letter of intent to sell its China Immunodiagnostics business for up to $200 million, citing persistent policy headwinds.
Leadership changes at the top analytical instrument vendors - a 2025-2026 scorecard
Sartorius installed a new chief in July 2025. Thermo Fisher and Danaher both have CFO and COO handovers landing in early 2026. Here is the running scorecard for analytical-instrument buyers.
Specialty chemicals M&A: carve-outs and corporate refocus dominate H1 2026
Specialty chemicals dealmaking through May 2026 leans on carve-outs and bolt-ons rather than transformative consolidation - BASF Coatings to Carlyle, an amended Honeywell-Johnson Matthey deal, Element Solutions on EFC.
Bruker Q1 2026: organic revenue dips as BSI bookings keep momentum
Bruker reported $823.4 million in Q1 2026 revenue, up 2.7% on a 4.5% FX tailwind, but organic growth was negative 4.4% even as BSI bookings rose at a high-single-digit pace for a third straight quarter.
Agilent Q1 FY2026: $1.80B revenue, all three segments grow ahead of May 27 print
Agilent reported $1.80 billion in first-quarter fiscal 2026 revenue, up 7.0% reported and 4.4% on a core basis, with all three operating segments growing ahead of the May 27 second-quarter release.
Thermo Fisher Q1 2026: analytical instruments revenue flat as academic demand weakens
Thermo Fisher's Analytical Instruments segment posted $1.72 billion in Q1 2026 revenue, flat year-on-year, with a 2% organic decline tied to softer academic and government demand.
BASF, Dow, LyondellBasell Q1 2026: chemicals capex thins, analytics goes brownfield
BASF, Dow, and LyondellBasell all reported Q1 2026 results that point to tight capex, footprint rationalisation, and cost programmes - shifting process-analytics demand toward brownfield retrofits, not greenfield builds.
Mettler-Toledo Q1 2026: process analytics rides semiconductor and bioprocessing demand
Mettler-Toledo reported $947.1 million in Q1 2026 sales, with management calling out process analytics as small but fast-growing on semiconductor fab build-outs, data-center cooling, and bioprocessing demand.
Process Raman launches stayed quiet through spring 2026; portfolio moves dominated
A scan of vendor press rooms over the March-May 2026 window turns up no new process Raman analyzers from the major suppliers. The visible motion was in adjacent inline analytics and lab-grade Raman.
Endress+Hauser refreshes Raman Rxn probe portfolio; Sartorius BioPAT pairing deepens
Updated spec sheets through late 2025 consolidate Endress+Hauser's Raman Rxn-10, -20, -30, -40 and -46 probes under one naming scheme, with the bioprocess Rxn-46 keyed to Sartorius BioPAT Spectro.